Skip Navigation

Neuro-Oncology 2006 8(2):119-126; doi:10.1215/15228517-2005-012
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Aboody, K. S.
Right arrow Articles by Perides, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Aboody, K. S.
Right arrow Articles by Perides, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 by the Society for Neuro-Oncology

Targeting of melanoma brain metastases using engineered neural stem/progenitor cells1

Karen S. Aboody2, Joseph Najbauer, Nils Ole Schmidt, Wendy Yang, Julian K. Wu, Yuzheng Zhuge, Wojciech Przylecki, Rona Carroll, Peter M. Black and George Perides

Divisions of Hematology and Hematopoietic Cell Transplantation and Neurosciences and Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA (K.S.A., J.N.); Neurosurgical Oncology Laboratory, Department of Neurosurgery, Brigham and Women's Hospital and Children's Hospital, Harvard Medical School, Boston, MA 02115, USA (K.S.A., N.O.S., W.Y., W.P., R.C., P.M.B.); Department of Neurosurgery, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany (N.O.S.); Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA (J.K.W., Y.Z., G.P.); and Departments of Surgery and Neurosurgery, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA (J.K.W., G.P.)

2 Address correspondence to Karen S. Aboody, City of Hope National Medical Center and Beckman Research Institute, Miller 109, 1500 East Duarte Road, Duarte, CA 91010-3000 (kaboody{at}coh.org).


  Abstract

Brain metastases are an increasingly frequent and serious clinical problem for cancer patients, especially those with advanced melanoma. Given the extensive tropism of neural stem/progenitor cells (NSPCs) for pathological areas in the central nervous system, we expanded investigations to determine whether NSPCs could also target multiple sites of brain metastases in a syngeneic experimental melanoma model. Using cytosine deaminase-expressing NSPCs (CD-NSPCs) and systemic 5-fluorocytosine (5-FC) pro-drug administration, we explored their potential as a cell-based targeted drug delivery system to disseminated brain metastases. Our results indicate a strong tropism of NSPCs for intracerebral melanoma metastases. Furthermore, in our therapeutic paradigm, animals with established melanoma brain metastasis received intracranial implantation of CD-NSPCs followed by systemic 5-FC treatment, resulting in a significant (71%) reduction in tumor burden. These data provide proof of principle for the use of NSPCs for targeted delivery of therapeutic gene products to melanoma brain metastases.

Keywords: brain metastases, cytosine deaminase, gene therapy, melanoma, neural progenitor cells, neural stem cells, tumor targeting

Received April 28, 2005; Accepted December 15, 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. Ganta, D. Chiyo, R. Ayuzawa, R. Rachakatla, M. Pyle, G. Andrews, M. Weiss, M. Tamura, and D. Troyer
Rat Umbilical Cord Stem Cells Completely Abolish Rat Mammary Carcinomas with No Evidence of Metastasis or Recurrence 100 Days Post-Tumor Cell Inoculation
Cancer Res., March 1, 2009; 69(5): 1815 - 1820.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
D. Zhao, J. Najbauer, E. Garcia, M. Z. Metz, M. Gutova, C. A. Glackin, S. U. Kim, and K. S. Aboody
Neural Stem Cell Tropism to Glioma: Critical Role of Tumor Hypoxia
Mol. Cancer Res., December 1, 2008; 6(12): 1819 - 1829.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Kucerova, V. Altanerova, M. Matuskova, S. Tyciakova, and C. Altaner
Adipose Tissue-Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Cancer Res., July 1, 2007; 67(13): 6304 - 6313.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Palmieri, A. F. Chambers, B. Felding-Habermann, S. Huang, and P. S. Steeg
The Biology of Metastasis to a Sanctuary Site
Clin. Cancer Res., March 15, 2007; 13(6): 1656 - 1662.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. K. Danks, K. J. Yoon, R. A. Bush, J. S. Remack, M. Wierdl, L. Tsurkan, S. U. Kim, E. Garcia, M. Z. Metz, J. Najbauer, et al.
Tumor-Targeted Enzyme/Prodrug Therapy Mediates Long-term Disease-Free Survival of Mice Bearing Disseminated Neuroblastoma
Cancer Res., January 1, 2007; 67(1): 22 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-K. Kim, S. U. Kim, I. H. Park, J. H. Bang, K. S. Aboody, K.-C. Wang, B.-K. Cho, M. Kim, L. G. Menon, P. M. Black, et al.
Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression.
Clin. Cancer Res., September 15, 2006; 12(18): 5550 - 5556.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.